Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

http://www.wikidata.org/entity/Q42285293

about

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Adverse reactions associated with systemic polymyxin therapy.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Polymyxin B versus colistin: an update.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients.Critical Need for Clarity in Polymyxin B Dosing Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.

P2860

Q28082546-C4B44945-3449-4AFC-855B-96432D136C3C Q34346283-59BA30D1-233B-4207-9C6F-0F93F2A7B988 Q36158501-E2B2BB7F-622C-43B8-AE81-F3C6ED37371A Q37014270-01F7BDD1-6DD1-4703-9F58-74CED7E8E941 Q37023206-C7DA63ED-B90F-4E09-8A24-76D6BF9728EC Q38138835-E93CCBE3-8E1E-4A7F-8794-53B0F8553EDC Q38255373-3644B2F9-F404-44F5-81A4-BDD83D56FF9F Q38262873-0318D9DB-4E34-4A3A-A29F-EF44F1D3514F Q38613051-610877FF-FCDB-4B2A-B7A6-B7A73E849716 Q38664871-7A529B0F-978A-4B09-9281-4A35ABF8DE5A Q38944862-9BAE1839-5AD1-4C4B-8D16-1A1E2F5B8A2F Q40195691-EF7E8B80-4CB3-4F70-BD3A-F1986D7D1C56 Q40587067-11A18681-87CA-4599-B688-FE93B386D1C8 Q40719307-8D0B2ABC-F0CD-4377-ABDC-EB499D623F5F Q41695443-7DD8105C-6A48-4C21-839A-D6EAD5371FF4 Q42199910-33BC3B11-6C91-4400-A47E-BE3019676B7C Q42358815-F7CE9797-C1AD-465D-B31D-788157FA983C Q43607805-DC824C75-D92C-44BF-B340-70438E51F6B5

P2860

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

http://www.wikidata.org/entity/Q42285293

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@en

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@nl

type

label

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@en

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@nl

prefLabel

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@en

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@nl

P1433

Q42285293-4AAE8DD5-E28D-4BBC-9AC6-AF36F8AA9102

P1476

Q42285293-144A853A-2926-46B1-B589-76A1D682105C

P2093

Q42285293-068647D6-D7A7-4969-9479-3C8C38B50EFF

Q42285293-16EFBBD9-B443-4821-BB80-589AE6AE6C56

Q42285293-2C8F4733-EC58-45DD-9296-56EA1B5836D9

Q42285293-3FFB6C93-4702-41FA-9BC7-B693AADD853E

Q42285293-41B13AC4-35B3-4ECC-9C11-F313F392A95B

Q42285293-73EF3062-08B9-4269-A3AC-D267E455D356

Q42285293-8A716792-C73B-4CEC-9D6E-8692393186E3

Q42285293-96148DB1-71B3-4A22-91EB-44D1BDCA5A00

Q42285293-BA6E4F19-EB6B-4DF7-BA86-EA01FB8779D8

Q42285293-D7D775C7-5A6D-449F-A378-378E28DADC12

P2860

Q42285293-10088BB7-4507-426B-AD04-B5697C4CE234

Q42285293-18D9A32E-86CE-4B90-85F4-900F619B6647

Q42285293-29EC96E8-1EEF-4EA7-A865-A933275AE19A

Q42285293-5CB6BB37-3654-4144-9987-723722FA94D5

Q42285293-799CADA4-F56F-4F54-9E78-7A2FE79C683C

Q42285293-7CEB142B-04D4-49FC-99CD-2AD3F0294556

Q42285293-80EB3474-9AC3-400B-B7CE-D503BD4E54CC

Q42285293-9C739E23-7E04-476A-A899-581438D0A9B3

Q42285293-9CD77E06-D6BF-4EBD-9729-A9CEFD910E71

Q42285293-D540B766-9060-46D3-80C8-F80C9A3360BB

P304

Q42285293-C340A1CD-B58D-4DFD-A991-70649E1EE553

P31

Q42285293-91B77C29-E8FF-441D-A424-979E8404F0EC

P356

Q42285293-9E261A2B-7110-45A8-B4D8-F4E0D8B4D2F6

P407

Q42285293-2875D071-4EC9-4E07-BA11-9153B446E576

P433

Q42285293-B7B4D99E-A240-47BB-BC34-3987ACFCF422

P478

Q42285293-10D38B17-8854-48DE-9620-939A11D0F9B2

P577

Q42285293-7DA5FE06-980B-4363-AB14-1555BD230C8C

P698

Q42285293-7CFFAABB-393F-4AE0-9805-F0D99248EAF9

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.

@en

P2093

Alan Forrest

http://www.w3.org/2001/XMLSchema#string

Alexandre P Zavascki

http://www.w3.org/2001/XMLSchema#string

Ana M Sandri

http://www.w3.org/2001/XMLSchema#string

Cornelia B Landersdorfer

http://www.w3.org/2001/XMLSchema#string

David Saitovitch

http://www.w3.org/2001/XMLSchema#string

Diego R Falci

http://www.w3.org/2001/XMLSchema#string

Jian Li

http://www.w3.org/2001/XMLSchema#string

Jiping Wang

http://www.w3.org/2001/XMLSchema#string

Jovan Jacob

http://www.w3.org/2001/XMLSchema#string

Micheline G Dalarosa

http://www.w3.org/2001/XMLSchema#string

P2860

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.

fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients

Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.

Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.

Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study.

P304

674-677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKS437

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23179561

http://www.w3.org/2001/XMLSchema#string